TESARO, Inc. (NASDAQ:TSRO) – Analysts at SunTrust Banks upped their FY2017 earnings estimates for shares of TESARO in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings per share of ($8.23) for the year, up from their prior estimate of ($10.40). SunTrust Banks has a “Buy” rating and a $160.00 price objective on the stock. SunTrust Banks also issued estimates for TESARO’s Q4 2017 earnings at ($2.41) EPS, Q3 2018 earnings at ($1.94) EPS, FY2018 earnings at ($7.52) EPS, FY2019 earnings at ($4.56) EPS and FY2020 earnings at $1.69 EPS.
Other equities analysts have also issued reports about the company. Credit Suisse Group set a $190.00 price target on TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. Lake Street Capital reaffirmed a “buy” rating and set a $143.00 price target on shares of TESARO in a research note on Thursday. Robert W. Baird reaffirmed a “hold” rating and set a $120.00 price target on shares of TESARO in a research note on Friday. HC Wainwright reaffirmed a “buy” rating on shares of TESARO in a research note on Wednesday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price target on shares of TESARO in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO has a consensus rating of “Hold” and a consensus price target of $161.72.
ILLEGAL ACTIVITY WARNING: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://ledgergazette.com/2017/11/12/tesaro-inc-tsro-to-post-fy2017-earnings-of-8-23-per-share-suntrust-banks-forecasts.html.
TESARO (TSRO) opened at $91.09 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 5.41. TESARO has a one year low of $89.00 and a one year high of $192.94.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm’s quarterly revenue was up 740.3% on a year-over-year basis. During the same period last year, the company posted ($1.72) EPS.
Several large investors have recently made changes to their positions in the stock. Hanseatic Management Services Inc. raised its holdings in shares of TESARO by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock worth $830,000 after acquiring an additional 15 shares in the last quarter. Stephens Inc. AR raised its holdings in shares of TESARO by 6.5% during the second quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 115 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in shares of TESARO by 1.1% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock worth $1,690,000 after acquiring an additional 136 shares in the last quarter. Aperio Group LLC raised its holdings in shares of TESARO by 4.5% during the second quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 156 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of TESARO by 6.3% during the second quarter. IFP Advisors Inc now owns 4,471 shares of the biopharmaceutical company’s stock worth $625,000 after acquiring an additional 265 shares in the last quarter.
In related news, VP Edward C. English sold 10,862 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,692 shares of company stock valued at $4,628,976. 40.50% of the stock is currently owned by insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.